Counterpoint Mutual Funds LLC Makes New Investment in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Counterpoint Mutual Funds LLC bought a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 156,439 shares of the company's stock, valued at approximately $727,000.

Several other hedge funds have also recently added to or reduced their stakes in GDRX. Swiss National Bank boosted its holdings in GoodRx by 4.1% during the fourth quarter. Swiss National Bank now owns 161,400 shares of the company's stock valued at $751,000 after purchasing an additional 6,400 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. raised its stake in GoodRx by 38.7% during the fourth quarter. Connor Clark & Lunn Investment Management Ltd. now owns 1,228,836 shares of the company's stock worth $5,714,000 after acquiring an additional 342,781 shares in the last quarter. Prescott Group Capital Management L.L.C. lifted its holdings in shares of GoodRx by 42.3% during the fourth quarter. Prescott Group Capital Management L.L.C. now owns 134,660 shares of the company's stock valued at $626,000 after acquiring an additional 40,000 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of GoodRx in the 4th quarter valued at $2,500,000. Finally, Aigen Investment Management LP bought a new stake in shares of GoodRx in the 4th quarter worth about $62,000. Institutional investors and hedge funds own 63.77% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on GDRX shares. Morgan Stanley cut their price target on shares of GoodRx from $7.00 to $6.00 and set an "equal weight" rating for the company in a report on Tuesday, December 17th. Wells Fargo & Company decreased their price target on GoodRx from $9.00 to $8.00 and set an "overweight" rating on the stock in a research report on Friday, February 28th. Citigroup reduced their target price on shares of GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a research report on Friday, January 10th. KeyCorp reduced their price objective on GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Finally, Mizuho started coverage on GoodRx in a research note on Wednesday, December 4th. They set a "neutral" rating and a $5.00 price target on the stock. Three investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, GoodRx presently has an average rating of "Moderate Buy" and an average target price of $8.18.

Remove Ads

GoodRx Trading Down 2.1 %

Shares of GDRX stock traded down $0.10 on Friday, reaching $4.64. The company had a trading volume of 3,709,457 shares, compared to its average volume of 1,350,583. The company has a 50-day moving average of $4.74 and a 200-day moving average of $5.45. GoodRx Holdings, Inc. has a 12 month low of $4.09 and a 12 month high of $9.26. The stock has a market cap of $1.78 billion, a PE ratio of -154.67, a PEG ratio of 2.46 and a beta of 1.25. The company has a current ratio of 5.48, a quick ratio of 5.48 and a debt-to-equity ratio of 0.70.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.